Meeting
2024 ASCO Gastrointestinal Cancers Symposium
PD-L1 as a predictor of chemo-immunotherapy response in biliary tract cancers: A systematic review and meta-analysis.
Authors
Juan Jose Juarez
Beth Israel Deaconess Medical Center, Boston, MA
Juan Jose Juarez , Soravis Alm Osataphan , Ben Ponvilawan , Nipith Charoenngam , Mary Linton Bounetheau Peters
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 541)
DOI
10.1200/JCO.2024.42.3_suppl.541
Abstract #
541
Poster Bd #
F8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
First Author: Mario Machado Lopes
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
First Author: Sun Young Jeong
Poster
2022 ASCO Annual Meeting
Nivolumab-based induction chemoimmunotherapy and PD-L1 expression in locoregionally advanced HPV-associated oropharyngeal squamous cell carcinoma.
First Author: Ari Rosenberg
Poster
2020 ASCO Virtual Scientific Program
Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis.
First Author: Ranjan Pathak